The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity
But the pricing landscape is shifting fast in 2026, with new oral options, a landmark Medicare program, and negotiated prices on the horizon
Retatrutide Update: UK Mounjaro Price Shock, Lillys AI Deal & PN-477 Rival 21 August 2025 Retatrutide is an investigational weekly injection designed to help with weight management by acting on three hormone receptors at once: GLP-1, GIP and glucagon by a company called Eli Lilly
Readers should understand that compounded GLP-1 availability may depend on current federal policy, state rules, individual pharmacy requirements, current shortage status, and clinician judgment
Kidney function significantly affects exenatide and lixisenatide clearance, but medications like semaglutide, tirzepatide, dulaglutide, and liraglutide undergo proteolytic degradation and do not require renal dose adjustments
they do not represent a licensed prescribing schedule